Compass Therapeutics Reports Positive Tovecimig Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Source: stocktwits
Compass Therapeutics Inc. experienced a significant decline of 75.15% in pre-market trading, hitting a 52-week low.
The company's recent clinical trial results for Tovecimig in combination with Paclitaxel showed an overall response rate of 17.1%, significantly higher than the 5.3% response rate for Paclitaxel alone. Despite this positive news, the stock price fell sharply, indicating a sector rotation as the broader market, represented by the Nasdaq-100, saw only a slight increase of 0.07%.
This decline in stock price, despite promising clinical results, reflects investor caution and market dynamics. Compass Therapeutics plans to engage with the FDA regarding these findings, which could influence future stock performance positively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPX
Wall Street analysts forecast CMPX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.050
Low
8.00
Averages
12.67
High
24.00
Current: 2.050
Low
8.00
Averages
12.67
High
24.00
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GT Biopharma Advances NK Cell Therapy with TriKE Platform
- Rise of NK Cell Therapy: GT Biopharma focuses on its TriKE platform to provide scalable, lower-toxicity cancer treatment options, addressing the limitations of T-cell therapies in solid tumors, which is expected to significantly enhance patient treatment experiences.
- Significant Clinical Progress: By 2026, GT Biopharma has advanced three TriKE candidates into clinical stages, with GTB-5550 receiving FDA approval and initiating Phase 1 trials targeting B7-H3 protein in solid tumors, showcasing its potential in treating refractory cancers.
- Massive Market Opportunity: GT Biopharma highlights that the global solid tumor market could reach hundreds of billions of dollars, with B7-H3 being an attractive target due to its broad expression across many common and hard-to-treat solid cancers, indicating a strong unmet medical need for its products.
- Complex Competitive Landscape: GT Biopharma faces fierce competition in NK cell biology from companies like Fate Therapeutics and Nkarta; despite being smaller, its unique TriKE platform and clinical advancements position it well within the rapidly evolving biotech sector.
See More
GT Biopharma Advances NK Cell Therapy with TriKE Platform
- Rise of NK Cell Therapy: GT Biopharma focuses on its TriKE platform to harness NK cells, aiming to provide scalable cancer treatment solutions that are expected to significantly reduce costs and toxicity, addressing the market's demand for safer therapies.
- Significant Clinical Progress: As of 2026, GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 receiving FDA clearance and initiating a Phase 1 trial targeting B7-H3 positive tumors, showcasing potential in the solid tumor space.
- Massive Market Opportunity: The company highlights that the global solid tumor market could reach hundreds of billions of dollars, with B7-H3 being an attractive target due to its broad expression across many difficult-to-treat cancers, presenting substantial commercial value and market appeal.
- Intense Competitive Landscape: While GT Biopharma is actively pursuing NK cell biology, it faces challenges from larger competitors like Fate Therapeutics, which has stronger capital and technological capabilities in cell therapy, indicating that market competition will continue to intensify.
See More
Compass Therapeutics Announces Upcoming Investor Events in June
- Investor Event Schedule: Compass Therapeutics will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, showcasing its latest advancements in anti-tumor therapies.
- Event Timing and Links: The Jefferies conference will start at 8:45 AM ET, while the Goldman Sachs conference is set for 8:00 AM ET, with provided webcast links allowing investors to view the presentations and stay updated on the company's developments.
- One-on-One Meeting Opportunities: Management will be available for one-on-one meetings during both events, enabling interested investors to request meetings through their representatives, thus facilitating deeper insights into the company's strategies and product pipeline.
- Company Background: Founded in 2014, Compass Therapeutics focuses on developing antibody-based therapeutics aimed at addressing multiple diseases by modulating angiogenesis and activating immune responses within the tumor microenvironment, demonstrating significant clinical development potential.
See More
Compass Therapeutics Reports Promising Phase 1 Results for CTX-8371
- Clinical Trial Results: Compass Therapeutics presented promising Phase 1 results for CTX-8371 at the 2026 ASCO Annual Meeting, demonstrating efficacy in patients with advanced malignancies previously treated with checkpoint inhibitors, particularly in non-small cell lung cancer, triple-negative breast cancer, and Hodgkin lymphoma.
- Efficacy Assessment: Among 15 patients who completed the dose-limiting toxicity evaluation, one triple-negative breast cancer patient achieved over a 90% reduction in tumor lesions, while a Hodgkin lymphoma patient exhibited a partial metabolic response, highlighting the drug's significant therapeutic potential.
- Good Tolerability: CTX-8371 was generally well tolerated across all dose levels, with no dose-limiting toxicities observed, indicating a favorable safety profile that supports further clinical investigations.
- Future Outlook: The company plans to report data from the initiated cohort expansions in NSCLC, TNBC, and HL in the fourth quarter of 2026, further validating the clinical potential of CTX-8371 and advancing its application in oncology.
See More
Compass Therapeutics Under Investigation as Stock Plummets 64.41%
- Investigation Launched: Pomerantz LLP is investigating on behalf of Compass Therapeutics investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns about corporate governance and compliance.
- Clinical Trial Results: On April 27, 2026, Compass announced that its phase 2/3 study met the key secondary endpoint of progression-free survival, yet failed to meet the overall survival endpoint, indicating limitations in the drug's efficacy.
- Stock Price Plunge: Following the disappointing clinical trial results, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, severely impacting investor confidence.
- Legal Implications: The stock price drop and subsequent investigation may expose the company to class action lawsuits, further exacerbating uncertainty in the market and increasing risks for investors.
See More
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating whether Compass Therapeutics, Inc. has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and seek legal remedies.
- Clinical Trial Results: On April 27, 2026, Compass announced that its drug tovecimig met a key secondary endpoint in treating biliary tract cancer, yet failed to meet another critical secondary endpoint related to overall survival, indicating the complexity of the study results.
- Stock Price Plunge: Following the disappointing clinical trial results, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Context: Pomerantz LLP is a renowned securities class action law firm with over 85 years of experience, focusing on advocating for victims of securities fraud and corporate misconduct, having historically recovered multimillion-dollar damages for class members.
See More
GT Biopharma Advances NK Cell Therapy with TriKE Platform
- Rise of NK Cell Therapy: GT Biopharma focuses on its TriKE platform to provide scalable, lower-toxicity cancer treatment options, addressing the limitations of T-cell therapies in solid tumors, which is expected to significantly enhance patient treatment experiences.
- Significant Clinical Progress: By 2026, GT Biopharma has advanced three TriKE candidates into clinical stages, with GTB-5550 receiving FDA approval and initiating Phase 1 trials targeting B7-H3 protein in solid tumors, showcasing its potential in treating refractory cancers.
- Massive Market Opportunity: GT Biopharma highlights that the global solid tumor market could reach hundreds of billions of dollars, with B7-H3 being an attractive target due to its broad expression across many common and hard-to-treat solid cancers, indicating a strong unmet medical need for its products.
- Complex Competitive Landscape: GT Biopharma faces fierce competition in NK cell biology from companies like Fate Therapeutics and Nkarta; despite being smaller, its unique TriKE platform and clinical advancements position it well within the rapidly evolving biotech sector.
See More
GT Biopharma Advances NK Cell Therapy with TriKE Platform
- Rise of NK Cell Therapy: GT Biopharma focuses on its TriKE platform to harness NK cells, aiming to provide scalable cancer treatment solutions that are expected to significantly reduce costs and toxicity, addressing the market's demand for safer therapies.
- Significant Clinical Progress: As of 2026, GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 receiving FDA clearance and initiating a Phase 1 trial targeting B7-H3 positive tumors, showcasing potential in the solid tumor space.
- Massive Market Opportunity: The company highlights that the global solid tumor market could reach hundreds of billions of dollars, with B7-H3 being an attractive target due to its broad expression across many difficult-to-treat cancers, presenting substantial commercial value and market appeal.
- Intense Competitive Landscape: While GT Biopharma is actively pursuing NK cell biology, it faces challenges from larger competitors like Fate Therapeutics, which has stronger capital and technological capabilities in cell therapy, indicating that market competition will continue to intensify.
See More
Compass Therapeutics Announces Upcoming Investor Events in June
- Investor Event Schedule: Compass Therapeutics will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, showcasing its latest advancements in anti-tumor therapies.
- Event Timing and Links: The Jefferies conference will start at 8:45 AM ET, while the Goldman Sachs conference is set for 8:00 AM ET, with provided webcast links allowing investors to view the presentations and stay updated on the company's developments.
- One-on-One Meeting Opportunities: Management will be available for one-on-one meetings during both events, enabling interested investors to request meetings through their representatives, thus facilitating deeper insights into the company's strategies and product pipeline.
- Company Background: Founded in 2014, Compass Therapeutics focuses on developing antibody-based therapeutics aimed at addressing multiple diseases by modulating angiogenesis and activating immune responses within the tumor microenvironment, demonstrating significant clinical development potential.
See More
Compass Therapeutics Reports Promising Phase 1 Results for CTX-8371
- Clinical Trial Results: Compass Therapeutics presented promising Phase 1 results for CTX-8371 at the 2026 ASCO Annual Meeting, demonstrating efficacy in patients with advanced malignancies previously treated with checkpoint inhibitors, particularly in non-small cell lung cancer, triple-negative breast cancer, and Hodgkin lymphoma.
- Efficacy Assessment: Among 15 patients who completed the dose-limiting toxicity evaluation, one triple-negative breast cancer patient achieved over a 90% reduction in tumor lesions, while a Hodgkin lymphoma patient exhibited a partial metabolic response, highlighting the drug's significant therapeutic potential.
- Good Tolerability: CTX-8371 was generally well tolerated across all dose levels, with no dose-limiting toxicities observed, indicating a favorable safety profile that supports further clinical investigations.
- Future Outlook: The company plans to report data from the initiated cohort expansions in NSCLC, TNBC, and HL in the fourth quarter of 2026, further validating the clinical potential of CTX-8371 and advancing its application in oncology.
See More
Compass Therapeutics Under Investigation as Stock Plummets 64.41%
- Investigation Launched: Pomerantz LLP is investigating on behalf of Compass Therapeutics investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns about corporate governance and compliance.
- Clinical Trial Results: On April 27, 2026, Compass announced that its phase 2/3 study met the key secondary endpoint of progression-free survival, yet failed to meet the overall survival endpoint, indicating limitations in the drug's efficacy.
- Stock Price Plunge: Following the disappointing clinical trial results, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, severely impacting investor confidence.
- Legal Implications: The stock price drop and subsequent investigation may expose the company to class action lawsuits, further exacerbating uncertainty in the market and increasing risks for investors.
See More
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating whether Compass Therapeutics, Inc. has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and seek legal remedies.
- Clinical Trial Results: On April 27, 2026, Compass announced that its drug tovecimig met a key secondary endpoint in treating biliary tract cancer, yet failed to meet another critical secondary endpoint related to overall survival, indicating the complexity of the study results.
- Stock Price Plunge: Following the disappointing clinical trial results, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Context: Pomerantz LLP is a renowned securities class action law firm with over 85 years of experience, focusing on advocating for victims of securities fraud and corporate misconduct, having historically recovered multimillion-dollar damages for class members.
See More
